Korea’s WLA status enables the first WHO desk-based GMP review
GCFLU and Varicella keep PQ status while cutting inspection costs
Generated Image by Perplexity AI
GC Biopharma’s latest WHO GMP renewal shows how Korea’s regulatory standing is reshaping its drugmakers' interactions with global agencies. The company renewed WHO GMP compliance for two WHO-prequalified vaccines through a document-only desk assessment without an on-site inspection. It is the first Korean manufacturer to do this for PQ products.
The key enabler is Korea’s designation as a WHO-Listed Authority (WLA). WLA status is granted to regulators demonstrating strong capabilities in evaluation, authorization, and GMP oversight. For these authorities, WHO may rely more on local inspections and adjust the scope and intensity of its audits. After Korea’s Ministry of Food and Drug Safety obtained WLA status for both pharmaceuticals and vaccines, WHO reviewed GC Biopharma’s influenza vaccine GCFLU and varicella vaccine Varicella based on documentation rather than a factory visit.
Routine GMP inspections are demanding for manufacturers. They require extensive facility checks, documentation updates, dedicated staff to handle the audit, and production adjustments to fit inspection schedules. By moving to a desk assessment, GC Biopharma cut inspection-related costs by more than half compared with a full on-site review, according to the company. Equally important, the firm maintained PQ status without significant production disruption, supporting a stable supply.
The two vaccines have been supplied to international agencies and public markets for years under WHO prequalification. The latest approval reconfirms GC Biopharma's quality and manufacturing track record for these products, including process validation, change-control history, and batch performance data. With the desk-based renewal completed, the company can maintain its existing PQ volumes while using fewer resources and apply the same experience to future PQ applications for new formulations or additional vaccines.
The broader question is how far this model will extend across Korea’s pharmaceutical and vaccine industry. Maintaining WLA status requires the national regulator to sustain performance and consistency. Manufacturers hoping for desk-based reviews must operate documentation and data systems that meet that standard. GC Biopharma’s case shows how Korea’s regulatory credibility can translate into concrete advantages for individual firms. Whether those advantages scale into higher productivity and stronger export competitiveness depends on how other companies and the sector respond.
By Min Byung-kwun, KDFN
kdf＠kdfnews.com
Tag
댓글
0